Detalhe da pesquisa
1.
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
Cell
; 184(15): 3949-3961.e11, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161776
2.
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
N Engl J Med
; 384(3): 238-251, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33332778
3.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
N Engl J Med
; 385(13): 1184-1195, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34347950
4.
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
N Engl J Med
; 385(23): e81, 2021 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34587383
5.
Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus.
J Infect Dis
; 225(10): 1765-1772, 2022 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33507266
6.
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
J Infect Dis
; 227(1): 23-34, 2022 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895508
7.
Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
Am J Respir Crit Care Med
; 204(1): 23-33, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33651675
8.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
JAMA
; 327(5): 432-441, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029629
9.
Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants.
Clin Infect Dis
; 73(11): e4400-e4408, 2021 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32897368
10.
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
N Engl J Med
; 378(26): 2475-2485, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782224
11.
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
N Engl J Med
; 378(26): 2486-2496, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782217
12.
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Gastroenterology
; 158(1): 111-122.e10, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31593702
13.
Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.
Ann Rheum Dis
; 80(4): 509-517, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33199274
14.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet
; 394(10209): 1638-1650, 2019 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31543428
15.
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
N Engl J Med
; 377(3): 211-221, 2017 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28538136
16.
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation.
Allergy
; 75(5): 1188-1204, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838750
17.
IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation.
J Allergy Clin Immunol
; 144(6): 1624-1637.e10, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562870
18.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
N Engl J Med
; 375(24): 2335-2348, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27690741
19.
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.
J Infect Dis
; 218(suppl_5): S612-S626, 2018 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860496
20.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Lancet
; 389(10086): 2287-2303, 2017 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28478972